Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 18.5
(0.11%)
HKD 18.5
(0.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.27 Billion CNY | 26.85% |
| 2022 | 2.58 Billion CNY | -4.76% |
| 2021 | 2.71 Billion CNY | 5.61% |
| 2020 | 2.56 Billion CNY | 0.48% |
| 2019 | 2.55 Billion CNY | 34.35% |
| 2018 | 1.9 Billion CNY | 19.28% |
| 2017 | 1.59 Billion CNY | 8.09% |
| 2016 | 1.47 Billion CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 2.72 Billion CNY | 0.0% |
| 2023 FY | 3.27 Billion CNY | 26.85% |
| 2023 Q2 | 1.28 Billion CNY | 0.0% |
| 2023 Q4 | 1.98 Billion CNY | 0.0% |
| 2022 Q4 | 1.28 Billion CNY | 0.0% |
| 2022 Q2 | 1.29 Billion CNY | 0.0% |
| 2022 FY | 2.58 Billion CNY | -4.76% |
| 2021 FY | 2.71 Billion CNY | 5.61% |
| 2021 Q2 | 1.29 Billion CNY | 0.0% |
| 2021 Q4 | 1.42 Billion CNY | 0.0% |
| 2020 FY | 2.56 Billion CNY | 0.48% |
| 2020 Q4 | 1.34 Billion CNY | 0.0% |
| 2020 Q2 | 1.22 Billion CNY | 0.0% |
| 2019 Q2 | 1.29 Billion CNY | 0.0% |
| 2019 FY | 2.55 Billion CNY | 34.35% |
| 2019 Q4 | 1.26 Billion CNY | 0.0% |
| 2018 FY | 1.9 Billion CNY | 19.28% |
| 2018 Q4 | 860.74 Million CNY | 0.0% |
| 2018 Q2 | 1.04 Billion CNY | 0.0% |
| 2017 Q4 | 475.76 Million CNY | 0.0% |
| 2017 Q1 | 398.86 Million CNY | 0.0% |
| 2017 Q2 | 398.86 Million CNY | 0.0% |
| 2017 FY | 1.59 Billion CNY | 8.09% |
| 2016 Q4 | 398.86 Million CNY | 0.0% |
| 2016 Q1 | 369 Million CNY | 0.0% |
| 2016 FY | 1.47 Billion CNY | 0.0% |
| 2016 Q2 | 369 Million CNY | 0.0% |
| 2015 Q4 | 369 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -3020.272% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | -74.335% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 2111.367% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 21443.468% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 6318.581% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -19528.117% |
| Essex Bio-Technology Limited | 275.25 Million HKD | -1090.695% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 11463.253% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 3189.623% |
| SSY Group Limited | 1.31 Billion HKD | -148.556% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -2412.209% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | -1127.676% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 14.964% |